Estonia Pharmaceuticals & Healthcare Report Q2 2015
Headline Expenditure Projections
- Pharmaceuticals: From EUR276mn (USD364mn) in 2013 to EUR292mn (USD391mn) in 2014; +5.9% in local currency terms and +7.5% in US dollar terms.
- Healthcare: EUR1.11bn (USD1.46bn) in 2013 to EUR1.16bn (USD1.55bn) in 2014; +4.3% in local currency terms and +5.9% in US dollar terms .
Estonia scores 52.1 out of 100 in BMI's adjusted Pharmaceutical Risk/Reward Index (RRI) tool, moving up one to ninth position out of the 20 key markets covered in Central and Eastern Europe. Estonia's Industry Rewards score is still the weakest part of its pharmaceutical profile. That it scores as high as it does is mainly due to above-average scores in the urban/rural split and pensionable population. As the population ages, the dominant types of disease will shift, with the emergence of many more long-lasting chronic conditions, cancers and degenerative illnesses. This will tip the ratio of working people to dependants towards the latter, increasing the pressure on overall funding for the healthcare system.
Key Trends And Developments
In November 2014, Vectura confirmed that its partner, Sandoz (Novartis), has been granted marketing authorisation by the pharmaceutical regulatory authorities in Estonia, Latvia and...
The Estonia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Estonia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Estonia pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for Estonia, to test other views - a key input for successful budgeting and strategic business planning in the Estonian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Estonian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Estonia.
- Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMIs forecast analysis, and taken together with BMIs political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
BMIs Pharmaceuticals and Healthcare Risk Reward Index
- Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per 000 population).
- Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
- Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
- Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
- OTC Drug Market: OTC sales (USDbn & % of total sales).
- Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMIs Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the markets risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMIs industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.
Despite growing in recent years, the absolute value of the Estonian pharmaceutical market remains small and will continue to remain a marginal market in the Central and Eastern European region. Low-co st generic drugs are prevalent i n the market, with doctors obliged to prescribe by international non-proprietary names (INNs), rather than branded names unless there is a specific medical reason for a branded product to be used. Despite the small size of the pharmaceuticals industry , it does have a strong biotechnology sector and multinational presence i n the market is increasing. There is also potential for manufacturers to use the country as a low-cost export base rather than as a destination.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Estonia 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2010-2018)
Prescription Drug Market Forecast
Table: Leading ATC Groups By Pharmaceutical Sales, 2004-2010 (%)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Estonia 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Estonia 2010-2018)
Generic Drug Market Forecast
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Estonia 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Estonia 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Estonia 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Estonia 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Estonia - GDP By Expenditure
Industry Risk Reward Ratings
Central And Eastern Europe Risk/Reward Ratings
Estonia Risk/Reward Ratings
Industry Trends And Developments
Table: Leading Causes of Death, 2005-2010
Table: Healthcare Expenditure By The HIF, 2006-2011 (EURmn)
Table: Reimbursement Spending By Key Therapeutic Area, 2010-2011 (EURmn)
Table: Medicinal Products Reimbursed For Insured Patients, 2009-2011 (EURmn)
Table: Members Of EBio, 2011
Table: Clinical Trials, 1991-2011
Intellectual Property Regime
Table: Key Health Insurance Indicators, 2007-2011
Table: Expenditure By Reimbursed Prescription Medicinal Products, 2005-2010 (EEK '000)
Table: Members Of The Association Of International Pharmaceutical Manufacturers In Estonia (APME)
Foreign Pharmaceutical Players
Table: Pharmacies And Pharmacy Market Ratios, 2004-2009
Merck & Co
Grindeks (incorporating Tallinn Pharmaceutical Plant)
Table: Estonia's Population By Age Group, 1990-2020 ('000)
Table: Estonia's Population By Age Group, 1990-2020 (% of total)
Table: Estonia's Key Population Ratios, 1990-2020
Table: Estonia's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it